Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 12, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share transactions and does not contain financial performance data.
Material Changes
The filing details specific transactions on June 8, 2006, involving the GlaxoSmithKline (US) Trust ("the GSK US Trust"):
- The Trust sold 426 ADR Shares on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of $55.23 per ADR share.
- The Trust transferred 885 ADR Shares to participants in the GlaxoSmithKline Share Value Plan.
- Directors Dr. J-P Garnier and Dr. M M Slaoui hold interests in the shares held by the GSK US Trust in the same capacity as other employees or former employees of SmithKline Beecham Corporation and its subsidiaries.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of ADR shares sold (426) and transferred (885) by the GSK US Trust on June 8, 2006.
- Confirm the transaction price of $55.23 per ADR share.
- Note that Directors Dr. J-P Garnier and Dr. M M Slaoui are beneficiaries of the GSK US Trust.
- Understand that this filing does not contain financial results or strategic updates for the company.